Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against GeneDx Holdings Corp. in the United States District Court for the District of Connecticut on behalf of purchasers of WGS common stock between April 16, 2025 and May 4, 2026. The complaint alleges the company and its executives made false or misleading statements and failed to disclose issues including the importance of Fabric Genomics, declining margins, and less durable average reimbursement rates. On May 4, 2026, GeneDx reported a first quarter 2026 loss per share of $0.28 and a $57.5 million loss from operations, lowered its 2026 revenue guidance by approximately $65 million at the midpoint, and took a $31.3 million write-down related to Fabric Genomics goodwill and intangible assets. Following this news, GeneDx shares fell by $33.42 per share, or approximately 50%, from $67.93 on May 4, 2026 to close at $34.51 on May 5, 2026. Investors have until August 3, 2026 to apply to the Court to be appointed as lead plaintiff.
GeneDx Holdings Corp.Class action lawsuit alleging securities law violations, with stock dropping 50% after earnings miss and guidance cut.